Lupin hits 52-week low on US observations

Shares of drug maker Lupiun fell over 1 per cent on the Bombay Stock Exchange, hitting 52-week low, after media report suggested that US FDA has issued Form 483 with three observations to company’s Goa plant. Reacting to the news, shares of the company declined as much as 1.31 per cent to hit 52-week low of Rs 1319.60 apiece on the Bombay Stock Exchange.

The scrip was currently

Biocon net declines 62% in Q4

India's biotechnology major Biocon Ltd has posted Rs 127 crore consolidated net profit for the fourth quarter (January-March) of fiscal 2016-17 as against Rs 333 crore in the same period year ago, registering a whopping decline of 62 per cent year-on-year (YoY).

In a regulatory filing on the BSE on Thursday night, the city-based pharmaceutical company said consolidated revenue for

CCI orders antitrust probe into Roche cancer drug

India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by bios

Dr Reddy's Lab launches Vytorin generic drug in US market

Drug major Dr Reddys Laboratories Ltd on Thursday said it has launched US health regulator approved Ezetimibe and Simvastatin tablets in the US market. “Dr Reddy's Laboratories has launched Ezetimibe and Simvastatin tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg, a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) tablets, in the United Stat

India's antitrust watchdog orders probe into Roche cancer drug

MUMBAI  - India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged

Zydus gets USFDA final nod for anti-hypertensive tablets

Pharma major Cadila Healthcare Ltd on Tuesday said it has received final approval from the US health regulator to market anti-hypertensive drug - Olmesartan Medoxomil tablets. “The company has received final approval from the USFDA to market Olmesartan Medoxomil tablets, in strengths of 5 mg, 20 mg and 40 mg,” Cadila Healthcare Ltd said in a filing to the Bombay Stock Exchange on Ap

Nifty Pharma has immediate support placed at 9870 levels - GEPL

Observation

* NIFTY PHARMA is one of the most underperforming sectoral indices, as it closed down by around 3.07% at 10208.50, as against a down move of 0.34% in benchmark NIFTY 50.

* The Sector had made a recent swing high @ 10806.80 in the month of Feb 2017, lower, as compared to Dec 2016. Thus it has failed to sustain at higher levels and

25/04/2017 5:13:50 PM | Posted in Broking Firm Views - Sector Report read full news
India to expand access to J&J's TB drug this year

MUMBAI  - India's top tuberculosis fighter said the government will expand access to Johnson & Johnson's breakthrough TB drug this year, but health experts warn much more needs to be done to eliminate the superbug by 2025.

India will make bedaquiline, one of just two new TB drugs marketed over the last 50 years, available at 140 government-run TB trea

Government policy would succeed if generic drug quality improves

 The Centre's steps to make doctors prescribe drugs by their generic names and not by their brand names may not have material impact without steps for improving the quality standards for drugs, investment banking firm Jefferies has said.

In a report issued on Sunday, Jefferies said: "In our view, without steps for improving quality standards for drugs available in the ma

Divi's Lab hits 52-week low as USFDA issues warning letter

Shares of Divi's Laboratories dipped nearly 4 per cent, hitting 52-week low, in early trade on the Bombay Stock Exchange after the company said that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam.

Reacting to the news, shares of the company declined as much as 3.82 per cent to hit 52-week low of Rs 607.00 apiece on the Bombay Stock Exchange.

Government to set up telemedicine centres in rural areas: Venkaiah Naidu

The Centre is in the process of setting up telemedicine centres in rural areas to allow patients have consultation with specialist doctors, Union Minister M Venkaiah Naidu said. The initiative will help people in making appointments at outpatient departments of hospitals, collect lab reports, share blood availability status in government hospitals that is accessible online, he said. Naidu said

Dr Reddy's to sell Progesterone capsules in US

Indian drug major Dr Reddy's Laboratories on Friday announced it would sell Progesterone capsules in the US market for therapeutic treatment of cardiovascular disorders, breast cancer and probable dementia.

"The generic capsules, approved by the US Food and Drug Administration (USFDA), are a therapeutic equivalent version of Prometrium," said the city-based pharma compan

Hold Jyothy Laboratories Ltd - Sharekhan

Key points

Stock surges by 16% in recent times; positives priced in:

Jyothy Laboratories’ (JLL) stock price has seen a strong run-up of ~16% in the last 15 days in the wake of Henkel AG (Henkel) getting more time to exercise its option of acquiring upto 26% stake in the company. Henkel has got an extensi

21/04/2017 3:52:11 PM | Posted in Broking Firm Views - Long Term Report read full news
Neutral On Natco Pharma Ltd - Sharekhan

Key points

* Delivers strong 91.3% return since initiation nine months ago; downgrade to Neutral on expensive valuation:

We had initiated coverage on Natco Pharma (Natco) through a viewpoint report dated June 8, 2016 on expectation of an exponential growth on the back of a strong product pipeline. In line wi

19/04/2017 1:06:39 PM | Posted in Broking Firm Views - Long Term Report read full news
Sell Lupin Ltd For Target Rs.1380.00 - Religare Sec

Lupin Limited

After its failed attempt to cross major hurdle around its medium term moving averages on daily chart, LUPIN has formed a fresh shorting pivot and looks all set for a fresh slide in near future.

 

Recommendation

Sell Lupin Limited April Future @ 1425-1430 Stoploss 144

19/04/2017 11:47:52 AM | Posted in Broking Firm Views - Short Term Report read full news
USFDA inspects Baroda plant, no observations issued: Alembic

Alembic Pharmaceuticals today said no observations were issued by US health regulator USFDA after inspection of its Baroda facility. The bio-equivalence facility was inspected by US Food & Drug Administration (USFDA) from March 6-10; March 13-17 and April 10-12, Alembic said in a filing to BSE. "There were no 483s issued by USFDA at the end of the inspection," it added.

India Pharmaceuticals - Q4 Preview - Subdued quarter - RCML

Q4 Preview: Subdued quarter

We expect a muted Q4FY17 for our pharma universe with revenue/ PAT growth of 4.4%/5.3% YoY. While the demonetisation overhang on domestic growth is fading, we forecast weak US sales growth QoQ (barring GNP), due to high competition in key products, base business erosion and limited key launches. With the exception of GNP and

17/04/2017 2:54:45 PM | Posted in Broking Firm Views - Sector Report read full news
Dr Reddy's surges as USFDA completes inspection of Srikakulam SEZ unit

Shares of Dr Reddy’s Laboratories jumped nearly 2 per cent on the Bombay Stock Exchange after the company on Friday announced that the US drug regulator has completed the audit of active pharmaceutical ingredients (APIs) manufacturing plant at Srikakulam special economic zone (SEZ) in Andhra Pradesh with no observations.

Following the development, shares of company gained as muc

Pharma Sector - 4QFY17E Results Preview - HDFC Sec

* 4QFY17E is likely to be a soft quarter for the Indian pharma sector. Overall, we expect 6.7% top line growth for our coverage universe. EBITDA for most companies is expected to remain flat on a high base of 4QFY16, which includes sales from bigger products like gAbilify, gGleevec and gGlumetza. However, we believe that operating performance is likely to have bottomed out, and companies like L

14/04/2017 3:25:46 PM | Posted in Broking Firm Views - Sector Report read full news
Pharma Sector - Q4FY17 result preview - ICICI Sec

We expect healthcare companies under our coverage to report mixed set of results for the quarter ended Mar'17. Strong performance would be registered by: 1) Glenmark on the back of continued exclusivity of generic Zetia, 2) Alkem laboratories on back of higher India contribution and low base, and 3) Natco Pharma due to continued exclusivity gain from generic Tamiflu and launch of generic En

14/04/2017 3:05:28 PM | Posted in Broking Firm Views - Sector Report read full news
IOLCP zooms 10% on receiving EUGMP Certification for pharma products

Shares of IOL Chemicals and Pharmaceuticals (IOLCP) rallied nearly 10 per cent on the Bombay Stock Exchange after the company said that it has received EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary, for its product Ibuprofen, Lamotrigine, Metformin Hydrochloride confirming compliance with principals of Good Manufacturing Practices as provided by European Union L

Update On Indoco Remedies Ltd - SPA Sec

Indoco Remedies is engaged in manufacturing, marketing and distribution of pharmaceutical products/services in domestic & international markets. Company has vast marketing network in domestic market and has supply agreements with companies like Actavis & Aspen to supply formulations to regulated markets. Company has 9 manufacturing facilities of which 4 are FDA approved. On account of F

13/04/2017 11:24:31 AM | Posted in Broking Firm Views - Long Term Report read full news
Buy Glenmark Pharmaceuticals Ltd For Target Rs.1098.00 - Reliance Sec

STOCK IN FOCUS

*Glenmark Pharmaceuticals (GNP) closed 1.9% higher, outperforming benchmark NIFTY by 2.4%

* US business is expected to show strong traction on the back of ramp-up in new approvals, price hike in Mupriocin ointment and some of key high-value launches i.e. gZetia (launched in Dec’16; FTF; 180-days exclusivi

13/04/2017 10:10:34 AM | Posted in Broking Firm Views - Short Term Report read full news
Shilpa Medicare gets EIR for Raichur facility

Shilpa Medicare said that has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facilities located at Raichur, Karnataka, which was inspected between December 12-16, 2016. The inspection has now been closed by the USFDA, the company said in a filing.

The company had